Cathepsin-D, a lysosomal aspartyl proteinase, is highly secreted by breast cancer cells and its over-expression by transfection stimulates cancer cell proliferation. The mechanism by which this protease aects proliferation remains, however, unknown. In order to determine whether proteolytic activity is necessary, we abolished its enzymatic activity using site-directed mutagenesis followed by stable transfection in 3Y1-Ad12 cancer cells. Substitution of the aspartic acid residue 231 by an asparagine residue in its catalytic site abrogated the cathepsin-D proteolytic activity but did not aect its expression level, processing or secretion. However, like wild-type cathepsin-D, this mutated catalytically-inactive cathepsin-D retained its capacity to stimulate proliferation of cells embedded in Matrigel or collagen I matrices, colony formation in soft agar and tumor growth in athymic nude mice. Addition on the mocktransfected cells, of either conditioned media containing the wild-type or the mutated pro-cathepsin-D, or of the puri®ed mutated pro-cathepsin-D, partially mimicked the mitogenic activity of the transfected cathepsin-D, indicating a role of the secreted pro-enzyme. Moreover, addition of two anti-cathepsin-D antibodies on the cathepsin-D transfected cells inhibited their proliferation, suggesting an action of the secreted pro-cathepsin-D via an autocrine loop. A synthetic peptide containing the 27-44 residue moiety of the cathepsin-D pro-fragment was, however, not mitogenic suggesting that a receptor for the pro-fragment was not involved. Furthermore, the cathepsin-D mitogenicity was not blocked by inhibiting the interaction of pro-cathepsin-D with the mannose-6-phosphate receptors. Our results altogether demonstrate that a mutated cathepsin-D devoid of catalytic activity is still mitogenic and suggest that it is acting extracellularly by triggering directly or indirectly a yet unidenti®ed cell surface receptor. Oncogene (2001) 20, 6920 ± 6929.
Introduction
Initially, it was believed that the major role of proteases in metastasis was to facilitate invasion of cancer cells by digesting the extra-cellular matrix and the basement membrane components (Liotta et al., 1986) . However, recent evidences suggest that proteases are also key regulators of tumor growth at both primary and metastatic sites (reviewed by Chambers and Matrisian, 1997; Edwards and Murphy, 1998) . Like proteases acting at a neutral pH, such as the plasminogen activator and the matrix metalloproteinases, the precursors of lysosomal proteases (e.g. procathepsin-B, D, and L) are also over-expressed and hyper-secreted by carcinoma cells (Sloane and Honn, 1984; Rochefort et al., 1987; Kane and Gottesman, 1990) . However, activation of these proteases requires an acidic pH which is rather found intra-cellularly in endosomes, lysosomes or phagosomes.
Cathepsin-D (cath-D) (EC 3.4.23.5) has been extensively studied in human breast cancer, and many independent clinical studies have associated its overexpression with an increased risk of metastasis (Rochefort, 1992; Ferrandina et al., 1997; Foekens et al., 1999) . Several reports have indicated that cath-D stimulates cell proliferation. The ®rst evidence came from the puri®ed pro-cath-D from MCF-7 breast cancer cells which doubled MCF-7 cell growth on plastic (Vignon et al., 1986) . We further showed that 3Y1-Ad12 rat tumor cells transfected with the human cath-D cDNA grew more rapidly either at low or high cell densities (Garcia et al., 1990) . Moreover, Vetvicka and colleagues reported that pro-cath-D is mitogenic in breast and prostate cancer cells (Fusek and Vetvicka, 1994; Vetvicka et al., 1999) .
Dierent mechanisms have been proposed to be responsible for the cath-D mitogenicity. On one hand, they might involve its action as a ligand by interaction of the mannose-6-phosphate (Man-6-P) moieties of cath-D with the Man-6-P/ insulin-like growth factor-2 (IGF-2) receptor (Mathieu et al., 1990; De Leon et al., 1996) or by interaction of its pro-peptide with an unknown cell surface receptor (Fusek and Vetvicka, 1994; Vetvicka et al., 1999) . Conversely, they might implicate its catalytic activity to activate growth factors (Briozzo et al., 1991; Rifkin, 1997) or to prevent secretion of growth inhibitors (Liaudet et al., 1995) .
One major question remains as to whether the catalytic activity of cath-D is necessary for its mitogenicity (reviewed by Rochefort and LiaudetCoopman, 1999) . To address this problem, we have generated an enzymatically-inactive cath-D by mutating an aspartic acid residue of its catalytic site. Here, we show that, after transfection into the 3Y1-Ad12 rat tumor cells, catalytically-inactive cath-D facilitates cell growth as eciently as the wild-type cath-D both in vitro and in vivo. Our results indicate that cath-D mitogenic activity does not require its catalytic activity. Moreover, we show that exogenous addition of procath-D on the mock-transfected cells partially mimicked the mitogenic activity of the transfected cath-D, whereas its pro-fragment alone was inecient. Furthermore, two antibodies speci®c to mature cath-D inhibit cell proliferation when added on cath-D transfected cells. Finally, we provide arguments indicating that neither the Man-6-P receptors nor a putative receptor speci®c for the cath-D pro-fragment were responsible for this mitogenic response.
Results
The cath-D catalytic site includes two aspartyl residues (33 and 231) respectively located on the 14 kDa and 34 kDa chains facing each other in their spatial con®guration (Metcalf and Fusek, 1993) . By using oligonucleotide-directed mutagenesis, a single A to G nucleotide substitution was made in amino acid positions 33 and/or 231 of human cath-D, changing an aspartic acid to an asparagine as indicated in Figure  1a . To assess the importance of the cath-D catalytic activity, we stably transfected the wild-type cath-D, or the single Asn 33, Asn 231, or double Asn 33-231 mutant cath-D constructs into 3Y1-Ad12 rat cancer cells that do not secrete endogenous pro-cath-D (Garcia et al., 1990) . We ®rst quanti®ed the amount of wild-type and mutated cath-D expressed by these pooled transfected cells with an immunoradiometric assay using monoclonal anti-human cath-D antibodies (Figure 1b) . The Asn 33 and Asn 33-231 mutants were expressed at a much lower level than the wild-type cath-D. The corresponding proteins might be either less stable or not well recognised by the M1G8 or D7E3 antibodies used in the immunoradiometric assay. Western blot and immunoprecipitation experiments with the M1G8 antibody con®rmed the lower expression of these two mutants which were, however, normally processed and secreted (data not shown). In contrast, the Asn 231 mutant was expressed as eciently as the wild-type cath-D, both intra-cellularly and as a secreted pro-enzyme. The cath-D concentration detected in cell extracts was in both cases 90+ 30 ng/mg DNA corresponding to 170+60 pmoles/mg cytosol protein, which is much higher than the median value used as a cut-o prognostic level in primary breast cancer (Rochefort, 1992; Ferrandina et al., 1997; Foekens et al., 1999) . The amount of the secreted procath-D was also similar in both transfectants, e.g., 17
to 22 ng/mg DNA/24 h corresponding to a concentration of 10 ± 15 nM pro-cath-D in the extra-cellular medium. The Asn 231 mutation did not alter cath-D processing and pro-cath-D secretion. As shown in Figure 1c , the Asn 231 mutated pro-cath-D was Cells were labelled for 6 h with [S 35 ]methionine. Cell lysates (C) and media (S) samples were immunoprecipitated with the M1G8 antibody, analysed on a 12% SDS ± PAGE and¯uorographed as described in Materials and methods. Equal protein amounts were loaded for the two transfected cell lines. Arrows indicate the migration of the three forms of cath-D. K=molecular mass in kDa normally processed into the 48 kDa and 34 kDa forms, and the 52 kDa pro-enzyme was secreted as eciently as the wild-type pro-cath-D. The Asn 231 mutation, however, completely inactivated the proteolytic activity of cath-D (Figure 2) . In contrast to the wild-type cath-D, neither the intra-cellular (Figure 2a (Figure 2c ). Thus, using this strategy, we generated an enzymatically-inactive, stable and normally processed and secreted Asn 231 mutated cath-D.
We next studied the eect of the Asn 231 mutation on the in vitro and in vivo cath-D mitogenic activities. Unlike the mock or non-transfected cells, both the wild-type and the Asn 231 mutated cath-D transfected cells grew eciently when embedded in Matrigel, a reconstituted basement membrane. This was shown by cell staining after 7 days of culture (Figure 3a , top panel) and by phase contrast microscopy after 4 days of culture (Figure 3a, bottom panel) . In the latter case, higher magni®cation showed a stellate morphology of colonies with protrusions sprouting in the surrounding Matrigel. Comparable mitogenic activities of the wildtype and Asn 231 mutated cath-D were obtained when cells were embedded in a collagen I matrix ( Figure 3b ). As can be seen in Figure 4 , time-course experiments in Matrigel evidenced that the wild-type and Asn 231 mutated cath-D transfectants had the same exponential growth with a doubling time of 2 days. By contrast, both the mock and the non-transfected cells did not grow in Matrigel (Figure 4) . We veri®ed that a second pool of cath-D and Asn 231 transfectants presented the same growth rate (data not shown). Finally, both the wild-type and Asn 231 mutated cath-D transfected cells formed colonies in soft agar and their number was signi®cantly increased as compared to the mocktransfected cells (Table 1) . At sacri®ce, the mean tumor weight was increased by 3.6-fold for both the cath-D and Asn 231 groups compared to the control group ( Figure 5b ). Local invasion of cutaneous tissue and muscle was identical for the cath-D and Asn 231 tumors and was more pronounced than for the control tumors. However, at the time of sacri®ce, no spontaneous metastases were detected macroscopically probably due to the rapid growth of the primary tumors. These data demonstrate that a cath-D devoid of its catalytic activity remains mitogenic both in vitro and in vivo. We then attempted to determine whether the secreted pro-enzyme or the intracellular enzyme were responsible for this mitogenic activity. We ®rst tested the eect of conditioned media from mock-transfected (control) cells, cath-D or Asn 231 transfectants on the growth of mock-transfected cells plated on a Matrigel matrix. Figure 6a shows that conditioned media containing the wild-type pro-cath-D or the pro-cath-D-Asn 231, added at a ®nal concentration of 10 nM and 5 nM respectively, corresponding to optimal cath-D mitogenic activity (Vignon et al., 1986) , signi®cantly stimulated the growth of the mock-transfected cells by 1.4-fold and 1.3-fold. We veri®ed by radioimmunometric assays that, after the 4 days incubation, the concentrations of pro-cath-D were unchanged. In this bioassay, the growth of cath-D and Asn 231 transfectants was increased respectively by 2.4-fold and twofold compared to the mock-transfected cells (Figure 6b ), the corresponding secreted pro-enzyme concentrations being respectively 4.7 and 3.5 nM, which are in the range of the pro-enzyme concentrations in the conditioned media (Figure 6a) . Moreover, the puri®ed pro-cath-D-Asn 231 (elution fraction F2) added at a ®nal concentration of 2.5 nM on the mocktransfected cells stimulated their growth by 1.6-fold while elution fraction F5, devoid of pro-cath-D-Asn 231, had no eect (Figure 7) . Therefore, pro-cath-D secreted by the cath-D and Asn 231 transfectants partially mimicked the mitogenic activity of the transfected cath-D suggesting an autocrine mechanism.
To support this mechanism, we then tested the eects of anti-cath-D antibodies added to the medium, on the cath-D mitogenic activity. The D8F5 monoclonal antibody speci®c for total cath-D (52 kDa, 48 kDa and 34 kDa forms) and described to prevent pro-cath-D binding and endocytosis (Freiss et al., 1988) , inhibited the proliferation of cath-D transfectants by 35.8%, almost to the level of the mock-transfected cells (Figure 8 ). By contrast, the M2E8 monoclonal antibody speci®c for the 52 kDa pro-enzyme and described to be ineective to prevent pro-cath-D binding and endocytosis (Freiss et al., 1988) , was inecient ( Figure  8 ). In addition, a rabbit polyclonal antibody speci®c for total cath-D, which blocked pro-enzyme endocytosis (MR Farnoud, personal communication), inhibited the proliferation of cath-D transfectants by 36.3%, whereas a control rabbit serum had no eect ( Figure  8) . Therefore, two antibodies that prevent pro-cath-D binding and endocytosis, neutralising the secreted proenzyme and not the intracellular cath-D, also inhibited the mitogenic activity of the transfected cath-D. Together, these results show that the secreted procath-D can mimic the mitogenic activity of the transfected cath-D and strongly suggest that pro-cath-D is acting extra-cellularly via an autocrine loop possibly by triggering directly or indirectly a cell surface receptor.
We ®nally investigated which part of the pro-cath-D protein was implicated in this eect. It has been proposed that the cath-D mitogenic activity is mediated by the second half (amino acids 27 to 44) of the cath-D pro-fragment (Fusek and Vetvicka, 1994; Vetvicka et al., 1999 ) that corresponds to amino acids 717 to 0 (numbering from Faust et al., 1985;  see Figure 1a ). However, a synthetic peptide containing the 27 ± 44 residue moiety of the cath-D profragment (cath-D pro-peptide), added at a ®nal concentration of 2.5 nM, was ineective to stimulate the growth of the mock-transfected cells (Figure 7 ). Higher concentrations of the cath-D pro-peptide up to 50 nM were also ineective (not shown). In addition, the entire cath-D pro-fragment (amino acids 1 ± 44) tested at a ®nal concentration of 20 nM, did not stimulate the proliferation of mock-transfected cells seeded on plastic substratum in the conditions described by Fusek and Vetvicka (1994) (data not shown). These data indicate that the receptor to this pro-fragment was unlikely to be responsible for the mitogenic activity of cath-D observed in our conditions. At present, the only identi®ed cell surface receptors known to interact with the secreted procath-D are the Man-6-P receptors. We tested the eect of an excess of free Man-6-P in conditions that totally compete for cath-D binding and endocytosis via these receptors Laurent-Matha et al., 1998) . Neither Man-6-P nor free glucose-6-phosphate (Glu-6-P; negative control) prevented the Matrigel outgrowth of cath-D or Asn 231 transfectants ( Figure  9a) . Free Man-6-P did not mimic cath-D activity on the mock-transfected cells since it had no eect on growth (Figure 9a ). These results exclude that the cath-D mitogenicity is transduced via the Man-6-P receptors in 3Y1-Ad12 cells. We ®nally studied binding and endocytosis of the [ (Figure 9b , lane S). An excess of Man-6-P, but not of Glu-6-P, only partially inhibited pro-cath-D binding and endocytosis, indicating the presence of a Man-6-P independent receptor for endocytosis that might be related with the cath-D mitogenic activity (Figure 9 ).
Discussion
It is generally assumed that the mechanism of mitogenic activity of proteases is due to their proteolytic activity, facilitating either growth factor release (Rifkin, 1997) , or growth inhibitor deterioration (Liaudet et al., 1995) , or proteolytic activation of a mitogenic receptor as shown for the thrombin receptor (Carney and Cunningham, 1978) . These eects are generally prevented by speci®c protease inhibitors (De Clerck and Imren, 1994) . The active aspartyl proteinases, which include the various pepsins, chymosins, cathepsin E and D, and renin consist of two lobes each of which contains a key aspartate residue. Together they position the peptide substrate and activate its hydrolysis. Mutation of one of these active site aspartate residues was sucient to eliminate enzymatic activity of pepsinogen (Lin et al., 1989) , immunode®-ciency virus (HIV) aspartyl proteinase (Kohl et al., 1988; Seelmeier et al., 1988) , and recombinant baculovirus-expressed cath-D mutated in the aspartate 33 residue (Wittlin et al., 1999) . First of all, we report that cath-D mutated in its catalytic site at the position 231 lost its enzymatic activity (Figure 2 ) but retained its stability, processing and secretion (Figure 1 ). This mutant was used as a tool to determine whether cath-D requires its enzymatic activity to be mitogenic. Here, we demonstrate that cath-D remains mitogenic in the absence of catalytic activity both in vitro and in vivo indicating that it does not operate as a protease to stimulate cell proliferation in our experimental conditions (Figures 3 ± 5; Table 1 ). The growth of the dierent transfectants was monitored in absence of anchorage in 3-dimensional matrices (Matrigel, collagen I, soft agar). We show that cath-D induces Matrigel outgrowth of cells that normally do not grow when embedded in such a matrix, suggesting that cath-D over-expression increases the transformed phenotype of these cells. Indeed, cell growth in a 3-dimensional matrix might optimise signal transduction between the extra-cellular proteins, cell membrane receptors and nuclear structures mimicking more closely the in vivo situation (Bissell et al., 1999) . In addition, culture in 3-dimensional matrix is known to augment protein secretion as described for casein (Emerman et al., 1977) and pro-cath-D in primary cultures of human breast cancer (Veith et al., 1983) .
Moreover, exogenous pro-cath-D can partially mimic the mitogenicity of the transfected cath-D and antibodies interacting with mature cath-D inhibit cell proliferation, indicating a possible role of the secreted pro-enzyme via an autocrine loop (Figures 6 ± 8) . The level of growth stimulation observed with the puri®ed pro-cath-D-Asn 231 was consistent with the stimulation obtained for breast cancer cell lines with puri®ed pro-cath-D (Vignon et al., 1986) . To our knowledge, this is the ®rst example of a protease remaining active as a mitogen after inactivation of its catalytic site. These data are in accordance with our previous failure to inhibit breast cancer cell proliferation by means of the aspartyl protease inhibitor pepstatin (data not shown). The extra-cellular action of cath-D as a secreted protein, but not as a protease, is consistent with the fact that this protease requires a low-pH for its catalytic activity that is typically found in acidic cellular vesicles but rarely in the extra-cellular environment (Montcourrier et al., 1994 (Montcourrier et al., , 1997 .
The Asn 231 mutant was as ecient as the wild-type cath-D in stimulating the growth of xenograft tumors in athymic mice ( Figure 5 ). Many independent clinical studies reported that cath-D over-expression in human breast cancer is associated with an increased risk of developing clinical metastasis (Rochefort, 1992; Ferrandina et al., 1997; Foekens et al., 1999) . It is therefore possible that this cath-D mitogenic activity also occurs in patients, thereby increasing the growth of micro-metastases that have spread before surgery. We do, however, not exclude that in vivo the wild-type cath-D acts both as a protease in acidic compartments and as an extra-cellular ligand at a physiological pH. The relative contribution of these two mechanisms may depend upon the extra-cellular pH of the microenvironment where the pro-enzyme is secreted.
Finally, we show that the cath-D mitogenic activity is not directly transduced via the Man-6-P receptors since free Man-6-P did not mimic the cath-D mitogenic activity on mock-transfected cells (Figure 9a ). The Figure 9 Eect of Man-6-P in excess on the growth of the wild-type and the Asn 231 mutated cath-D transfected cells (a) and on pro-cath-D endocytosis (b). (a) Matrigel outgrowth of the control (mock-transfected), cath-D, and Asn 231 cells in the presence of free Man-6-P. Cells were embedded in a Matrigel matrix in the absence or presence of 10 mM Man-6-P or 10 mM Glu-6-P (negative control) and after 7 days' culture in a 24-well plate, cells were stained with p-nitrotetrazolium violet. Similar results were obtained in another independent experiment and also with cells plated on the Matrigel matrix. (b) Eect of free Man-6-P on the internalization of 35 S-labeled pro-cath-D via the Man-6-P receptors. Non-transfected 3Y1-Ad12 cells were incubated in the absence or presence of 10 mM Man-6-P or 10 mM Glu-6-P (negative control) for 24 h with 3610 6 c.p.m. TCA-precipitable proteins from 35 S-labeled medium conditioned by cath-D transfectants. After washing, cell lysates were analysed by SDS ± PAGE after immunoprecipitation with the M1G8 antibody as described in Materials and methods. S=pro-cath-D immunoprecipitated from incubated labeled medium Man-6-P/IGF-2 receptor is a multifunctional receptor, binding IGF-2 and Man-6-P bearing molecules on distinct sites (reviewed by Vignon and Rochefort, 1992) . Our laboratory has previously demonstrated that excess Man-6-P competes with Man-6-P bearing molecules but not with IGF-2 in Man-6-P/IGF-2 receptor binding (Mathieu et al., 1990) . Here, we can exclude a cath-D action by displacement of IGF-2 from the Man-6-P/IGF-2 receptor to the mitogenic insulin-like growth factor-1 (IGF-1) receptor since Man-6-P did not aect the growth of cath-D or Asn 231 transfectants on Matrigel (Figure 9a ). This work, along with the evidence that pro-cath-D can be endocytosed in breast cancer cells via a saturable receptor dierent from the Man-6-P receptors (Laurent-Matha et al., 1998) , strongly suggests that cath-D is mitogenic independently of its binding and action through the Man-6-P receptors. We ®nally show that pro-cath-D still binds to and is partially endocytosed in 3Y1-Ad12 cells even in the presence of an excess of free Man-6-P suggesting the existence of an alternative receptor that might mediate the cath-D mitogenic activity (Figure 9b ). Vetvicka and colleagues have described a mitogenic activity of the cath-D profragment moiety (amino acids 27 ± 44) on cancer cell lines maintained in serum-free conditions suggesting an interaction of its pro-part with an unknown cell surface receptor (Fusek and Vetvicka, 1994; Vetvicka et al., 1999) . However, we have not been able to reproduce this eect when the synthetic peptide 27 ± 44 was tested on breast cancer cells seeded on plastic substratum in various conditions including that described by Fusek and Vetvicka (1994) (unpublished experiments from our laboratory) or on the 3Y1-Ad12 cells plated on Matrigel (Figure 7 ) or on plastic (not shown). Furthermore, the M2E8 antibody speci®c for the proenzyme did not inhibit cell proliferation in contrast with D8F5 antibody interacting with the large chain (34 kDa) of cath-D (Figure 8) , showing that interference with the pro-domain had no eect. Together, these observations indicate that a receptor to this profragment was unlikely to be responsible for the mitogenic activity of cath-D detected in our conditions.
In conclusion, our results demonstrate that a mutated cath-D can stimulate cell growth without its catalytic activity and suggest that pro-cath-D is acting as an extra-cellular ligand, but not as a protease, by triggering directly or indirectly a yet unidenti®ed cell surface receptor. This work might ultimately lead to the development of new therapeutic strategies designed to block cath-D action in cancer cells by inhibiting its interaction with a cell surface receptor coupled to a mitogenic pathway rather than its proteolytic activity.
Materials and methods

Generation of constructs
Cath-D mutations were made by site-directed mutagenesis (Stratagene) on the 2 kb full-length human pre-pro-cath-D cDNA isolated from a MCF-7 breast cancer library (Garcia et al., 1990) inserted into the XbaI-EcoRI site of the pSP64 vector (Promega). Oligonucleotides (Eurogentec) containing an AAC codon (asparagine) instead of a GAC codon (aspartic acid) were used to mutate the Asp 33 and Asp 231 residues. Amino acid numbering is according to Faust et al. (1985) . Mutations were con®rmed by DNA sequencing. The full-length wild-type or mutated human pre-pro-cath-D cDNAs were then sub-cloned into the XbaI-EcoRI. site of pcDNA3.1(-) vector (Invitrogen).
Cell lines, transfections and growth assays
The 3Y1-Ad12 rat tumor cell line (Garcia et al., 1990) was cultured in RPMI 1640 medium with 5% fetal calf serum (FCS, GibcoBRL). Cells were transfected with the wild-type or mutated cath-D or the empty pcDNA3.1(-) vector alone using Lipofectamine (GibcoBRL) in serum-free medium (Optimem, GibcoBRL) and were then selected for resistance to G418 (400 mg/ml, Sigma). All experiments using transfected cells were performed from passages 4 ± 12 and the stability of human cath-D expression was controlled in this period. For Matrigel outgrowth assays, 100 000 sub-con¯uent cells were harvested and re-suspended in Matrigel (0.2 ml, 6.3 mg/ml) (Becton and Dickinson), an extra-cellular matrix extracted from Engelbreth-Holm-Swarm (EHS) mouse tumor, at 48C and then quickly added to a pre-set Matrigel layer in 24-well plates as described (Thompson et al., 1992) . The top Matrigel cell layers were gelled at 378C for 30 min, and then covered with culture medium with 5% FCS (0.5 ml). For treatment of cells embedded in Matrigel, compounds (e.g. Man-6-P, Glu-6-P) were added to the Matrigel layers and to the culture medium. For growth on the Matrigel matrix, 100 000 sub-con¯uent cells were plated on a pre-set Matrigel layer (0.2 ml, 6.3 mg/ml) in 24-well plates and then covered with culture medium with 0.75% FCS (0.5 ml). For treatment of cells plated on the Matrigel matrix, conditioned media (0.5 ml) or compounds (e.g. puri®ed pro-cath-D-Asn231, cath-D pro-peptide 27-44, control peptide M20, anti-cath-D antibodies: M2E8, D8F5, rabbit polyclonal, or rabbit serum) were directly added after attachment. To prepare the conditioned media, control, cath-D or Asn 231 cells were plated at a low density and after 24 h, cells were washed twice with culture medium without FCS and then cultured with 0.75% FCS. After 4 days in 0.75% FCS, cells reached 70% con¯uence and the conditioned medium was removed and centrifuged at 800 g for 10 min and ®nally stored at 7808C for subsequent experiments. The entire pro-fragment of 52 kDa pro-cath-D was provided by M. Fusek (Louisville, KY, USA) (Fusek and Vetvicka, 1994) . The cath-D pro-fragment peptide (amino acids 27-44) was synthesized by Eurogentec and its purity was veri®ed by HPLC. The control peptide M20 corresponds to amino acids 1793-1812 of the mouse BRCA1 (Santa Cruz Biotech.). Two mouse monoclonal antibodies raised against pro-cath-D were used: D8F5 (Garcia et al., 1985) and M2E8 (Freiss et al., 1988) , which interact speci®cally with total cath-D (52 kDa, 48 kDa and 34 kDa forms) and 52 kDa, respectively. The rabbit anti-cath-D antibody raised against total cath-D was purchased at DAKO (S.A.). Cells growing into or on Matrigel were recovered with 3 ml of Matrisperse (Becton and Dickinson), ®xed with methanol and their DNA content was determined by the diaminobenzoic acid¯uores-cence assay (Vignon et al., 1986) . Quanti®cation of cells in Matrigel was checked to be linear from 100 000 to 5 000 000 embedded cells and from 100 000 to 1 000 000 plated cells. For collagen I outgrowth, 100 000 sub-con¯uent cells were embedded in a collagen I gel at 48C (0.2 ml, 0.5 mg/ml) (Becton and Dickinson) and then added on a pre-set rat tail collagen I layer (0.2 ml, 0.5 mg/ml) in 24-well plates as described (Veith et al., 1983) and supplemented with culture medium containing 5% FCS. Soft agar assays were performed using 20 000 cells per 35 mm Petri dish (Fang et al., 1992) .
Protein labeling, immunoprecipitation, purification and immunoassay
Cells were incubated in methionine-free DMEM supplemented with 200 mCi/ml [ 35 S]methionine (41000 mCi/mmol, Amersham) for 6 h. Labeled proteins were immunoprecipitated with the anti-cath-D antibody (M1G8, 80 mg/ml), analysed by 12% SDS ± PAGE and¯uorography . For pro-cath-D-Asn 231 puri®cation, Asn 231 transfectants at 80% con¯uency were washed twice with culture medium without FCS and incubated for 24 h in absence of FCS. Conditioned medium was removed, centrifuged at 800 g for 10 min and stored at 7808C. Procath-D-Asn 231 was puri®ed from the conditioned medium in the absence of detergent using a one-step procedure on a M1G8 Sepharose anity column (Capony et al., 1989) modi®ed as described (Laurent-Matha et al., 1998) and eluted with 20 mM lysine, pH 11. The eluate was then adjusted to pH 7.4 with 1 M Hepes buer and the purity of the 52 kDa pro-cath-D recovered after elution was analysed on a 12% SDS ± PAGE by silver staining (Pharmacia Biotech). Intra-cellular and secreted human cath-D were quanti®ed using a cath-D immunoradiometric assay that does not cross-react with rodent cath-D (Garcia et al., 1985) .
Proteolytic activity assays
Conditioned media were collected after 24 h incubation of cells in serum-free medium and cell extracts were prepared by adding cold extraction buer (10 mM Tris-HCl pH 7.4, 1.5 mM EDTA, 0.1% thioglycerol) followed by ®ve freezethaw cycles. Total proteins from conditioned media (7 mg) or from cell extracts (50 mg) were incubated with 30 000 c.p.m. [ 14 C]methemoglobin (New England Nuclear, Boston, MA, USA), 2 mg of unlabeled methemoglobin (Sigma), in a citrate reaction buer (pH 2.5-4.5) (100 ml, ®nal volume) and in the absence or presence of 2 mM pepstatin (Sigma) . The proteolytic activity was calculated from the TCA-soluble radioactivity per microgram of DNA extracted from the corresponding cells.
Tumor growth in animals
Cells were trypsinized, washed, centrifuged, resuspended in cold PBS (GibcoBRL) and mixed with an equal volume of cold Matrigel (10 mg/ml). A total volume of 0.3 ml containing (400 000) cells was subcutaneously injected into 6-weekold Balb/c athymic female nude mice (IFFA CREDO). Injected mice were examined every 2 days for tumor appearance and tumor sizes were estimated from the product of the two perpendicular diameters.
